BRKR Stock Forecast 2025-2026
Distance to BRKR Price Targets
BRKR Price Momentum
🤔 Considering Bruker (BRKR)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Latest BRKR Stock Price Targets & Analyst Predictions
Based on our analysis of 19 Wall Street analysts, BRKR has a bullish consensus with a median price target of $72.00 (ranging from $55.00 to $80.00). The overall analyst rating is Strong Buy (8.3/10). Currently trading at $45.97, the median forecast implies a 56.6% upside. This outlook is supported by 10 Buy, 5 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Derik De Bruin at B of A Securities, projecting a 74.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BRKR Analyst Ratings
BRKR Price Target Range
Latest BRKR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BRKR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 24, 2025 | Guggenheim | Subbu Nambi | Buy | Reiterates | $0.00 |
| Feb 14, 2025 | Stifel | Daniel Arias | Hold | Maintains | $57.00 |
| Feb 14, 2025 | Barclays | Luke Sergott | Overweight | Maintains | $60.00 |
| Feb 10, 2025 | Barclays | Luke Sergott | Overweight | Maintains | $65.00 |
| Jan 17, 2025 | Guggenheim | Subbu Nambi | Buy | Reiterates | $0.00 |
| Dec 19, 2024 | Guggenheim | Subbu Nambi | Buy | Initiates | $72.00 |
| Dec 13, 2024 | B of A Securities | Derik De Bruin | Buy | Maintains | $80.00 |
| Dec 10, 2024 | UBS | Dan Leonard | Neutral | Assumes | $66.00 |
| Dec 5, 2024 | Goldman Sachs | Matthew Sykes | Neutral | Upgrade | $60.00 |
| Nov 6, 2024 | TD Cowen | Dan Brennan | Hold | Maintains | $70.00 |
| Nov 6, 2024 | Citigroup | Patrick Donnelly | Buy | Maintains | $75.00 |
| Nov 6, 2024 | Wells Fargo | Brandon Couillard | Overweight | Maintains | $75.00 |
| Nov 6, 2024 | Barclays | Terence Malone | Overweight | Maintains | $69.00 |
| Oct 15, 2024 | Barclays | Terence Malone | Overweight | Initiates | $75.00 |
| Sep 30, 2024 | Wolfe Research | Doug Schenkel | Peer Perform | Downgrade | $0.00 |
| Aug 27, 2024 | Wells Fargo | Brandon Couillard | Overweight | Initiates | $78.00 |
| Aug 7, 2024 | TD Cowen | Max Masucci | Hold | Maintains | $72.00 |
| Jul 11, 2024 | Citigroup | Buy | Maintains | $0.00 | |
| Jul 10, 2024 | Citigroup | Patrick Donnelly | Buy | Maintains | $80.00 |
| Jul 9, 2024 | Goldman Sachs | Matthew Sykes | Sell | Maintains | $60.00 |
Bruker Corporation (BRKR) Competitors
The following stocks are similar to Bruker based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Bruker Corporation (BRKR) Financial Data
Bruker Corporation has a market capitalization of $6.95B with a P/E ratio of 60.3x. The company generates $3.37B in trailing twelve-month revenue with a 3.4% profit margin.
Revenue growth is +14.6% quarter-over-quarter, while maintaining an operating margin of +16.7% and return on equity of +7.1%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Bruker Corporation (BRKR) Business Model
About Bruker Corporation
Develops high-performance scientific instruments and solutions.
Bruker Corporation generates revenue by designing and manufacturing advanced scientific instruments and analytical solutions that cater to various industries such as life sciences, medical diagnostics, and material analysis. Their instruments are critical in sectors like pharmaceuticals and environmental science, supporting research and development efforts.
Headquartered in Billerica, Massachusetts, Bruker has a global footprint and is recognized for its innovation in technologies like magnetic resonance, mass spectrometry, and X-ray systems. The company plays a vital role in scientific advancement, making its tools indispensable in both industrial and academic research settings.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
11,396
CEO
Dr. Frank H. Laukien Ph.D.
Country
United States
IPO Year
2000
Website
www.bruker.comBruker Corporation (BRKR) Latest News & Analysis
BRKR has launched the X4 POSEIDON, an advanced XRM for 3D microscopy, targeting industrial and scientific applications.
BRKR's launch of the X4 POSEIDON enhances its product portfolio, potentially boosting revenue and market competitiveness in the growing 3D microscopy sector.
Bruker Corporation (Nasdaq: BRKR) launched the X4 POSEIDON, a high-performance 3D X-ray microscope using microCT, enhancing accessibility for industrial and research applications.
Bruker's launch of the X4 POSEIDON enhances its product portfolio, potentially boosting revenue through increased market share in industrial and scientific sectors, signaling growth prospects for investors.
Bruker Corporation (Nasdaq: BRKR) announced advancements in 4D-Proteomics™ at the US HUPO Conference, enhancing peptide and protein identification for single-cell proteomics.
Bruker's advancements in 4D-Proteomics™ enhance its competitive edge in biotechnology, potentially leading to increased market demand and revenue growth.
Bruker Announces Quarterly Dividend
22 days agoBruker Corporation (Nasdaq: BRKR) announced a quarterly cash dividend of $0.05 per share, payable on March 28, 2025, to shareholders of record by March 17, 2025.
Bruker Corporation's dividend announcement signals financial stability and commitment to returning value to shareholders, which can enhance investor confidence and attract new investment.
Bruker Corporation (Nasdaq: BRKR) will unveil advancements in spatial biology, including the first Whole Transcriptome Panel, at the 2025 AGBT General Meeting.
Bruker's advancements in spatial biology could enhance its competitive edge and drive future revenue growth, impacting stock performance and investor sentiment positively.
Bruker Corporation (Nasdaq: BRKR) has appointed Laura Francis as an independent director effective February 18, 2025. She will also join the Audit Committee after the May 2025 shareholder meeting.
The appointment of Laura Francis as an independent director enhances Bruker's board with financial expertise, potentially improving governance and strategic decision-making, which can positively impact investor confidence.
Frequently Asked Questions About BRKR Stock
What is Bruker Corporation's (BRKR) stock forecast for 2025?
Based on our analysis of 19 Wall Street analysts, Bruker Corporation (BRKR) has a median price target of $72.00. The highest price target is $80.00 and the lowest is $55.00.
Is BRKR stock a good investment in 2025?
According to current analyst ratings, BRKR has 10 Buy ratings, 5 Hold ratings, and 0 Sell ratings. The stock is currently trading at $45.97. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for BRKR stock?
Wall Street analysts predict BRKR stock could reach $72.00 in the next 12 months. This represents a 56.6% increase from the current price of $45.97. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Bruker Corporation's business model?
Bruker Corporation generates revenue by designing and manufacturing advanced scientific instruments and analytical solutions that cater to various industries such as life sciences, medical diagnostics, and material analysis. Their instruments are critical in sectors like pharmaceuticals and environmental science, supporting research and development efforts.
What is the highest forecasted price for BRKR Bruker Corporation?
The highest price target for BRKR is $80.00 from Derik De Bruin at B of A Securities, which represents a 74.0% increase from the current price of $45.97.
What is the lowest forecasted price for BRKR Bruker Corporation?
The lowest price target for BRKR is $55.00 from at , which represents a 19.6% increase from the current price of $45.97.
What is the overall BRKR consensus from analysts for Bruker Corporation?
The overall analyst consensus for BRKR is bullish. Out of 19 Wall Street analysts, 10 rate it as Buy, 5 as Hold, and 0 as Sell, with a median price target of $72.00.
How accurate are BRKR stock price projections?
Stock price projections, including those for Bruker Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
